Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
GLAXOSMITHKLINE NZ LIMITED,Dostarlimab-gxly,"endometrial cancer, treatment of advanced or recurrent, irrespective of dMMR status, second line",Dostarlimab-gxly (Jemperli),Recommended for decline,Hospital,
